Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adultsOral ANAVEX®3-71 tablet ...

Myopia, a leading cause of visual impairment globally, can progress to serious complications like retinal and choroidal degeneration. While atropine is commonly used to manage childhood myopia, its ...

Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...

Schizophrenia care is shifting. In this article, Dr. Stella Sarraf, founder and CEO of Spinogenix, and Dr. David Walling, co-founder and chief clinical officer at Cenexel, discuss a new frontier: ...

By Sneha S K and Patrick Wingrove (Reuters) -Bristol Myers Squibb (BMS) plans to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price, it said on Monday.

Multiple sclerosis (MS) degrades the protective insulation around nerve cells, leaving their axons, which carry electrical impulses, exposed like bare wires. This can cause devastating problems with ...